Sanofi (SNY) Stock Forecast & Price Target

$51.63 -0.21 (-0.41%)

As of 10:18 AM Eastern

Sanofi - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 5 Analyst Ratings

Sell
0

Hold
2

Buy
3

Based on 5 Wall Street analysts who have issued ratings for Sanofi in the last 12 months, the stock has a consensus rating of "Buy." Out of the 5 analysts, 2 have given a hold rating, 1 has given a buy rating, and 2 have given a strong buy rating for SNY.

Consensus Price Target

$62.50
21.05% Upside

According to the 5 analysts' twelve-month price targets for Sanofi, the average price target is $62.50. The highest price target for SNY is $65.00, while the lowest price target for SNY is $60.00. The average price target represents a forecasted upside of 21.05% from the current price of $51.63.

Get the Latest News and Ratings for SNY and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Sanofi and its competitors.

SNY Analyst Ratings Over Time

Type	Current Forecast 4/15/24 to 4/15/25	1 Month Ago 3/16/24 to 3/16/25	3 Months Ago 1/16/24 to 1/15/25	1 Year Ago 4/16/23 to 4/15/24
Strong Buy	2 Strong Buy rating(s)	2 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	1 Buy rating(s)	1 Buy rating(s)	1 Buy rating(s)	2 Buy rating(s)
Hold	2 Hold rating(s)	1 Hold rating(s)	1 Hold rating(s)	3 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$62.50	$60.00	$57.50	$55.00
Forecasted Upside	21.05% Upside	3.90% Upside	16.47% Upside	18.94% Upside
Consensus Rating	Buy	Buy	Buy	Hold

Remove Ads

SNY Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

SNY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Sanofi Stock vs. The Competition

Type	Sanofi	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.82	2.54
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	20.56% Upside	25,202.61% Upside	25.81% Upside
News Sentiment Rating	Positive News See Recent SNY News	Positive News	Positive News

Remove Ads

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
3/21/2025	The Goldman Sachs Group 3 of 5 stars	James Quigley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$65.00	+12.48%
1/30/2025	Sanford C. Bernstein 3 of 5 stars	F. Cespedes Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
1/30/2025	Deutsche Bank Aktiengesellschaft 3 of 5 stars		Upgrade	Sell ➝ Hold
9/17/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	P. Verdult Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/26/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$55.00 ➝ $60.00	+13.92%
1/23/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Equal Weight	$55.00	+8.20%
12/5/2023	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Overweight ➝ Neutral
10/30/2023	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold
9/5/2023	Berenberg Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy
7/14/2023	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 10:06 AM ET.

Should I Buy Sanofi Stock? SNY Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, April 8, 2025. Please send any questions or comments about these Sanofi pros and cons to contact@marketbeat.com.

Sanofi
Bull Case

Here are some ways that investors could benefit from investing in Sanofi:

Sanofi has recently received a "strong-buy" rating from Sanford C. Bernstein, indicating strong confidence from analysts in the company's future performance.
The stock is currently trading at $54.62, which is near its 1-year high of $60.12, suggesting potential for growth as it approaches previous highs.
Institutional interest is growing, with several hedge funds, including Congress Wealth Management LLC and Rahlfs Capital LLC, recently acquiring significant stakes in Sanofi, reflecting confidence in the company's prospects.
Sanofi has a solid market capitalization of approximately $138.62 billion, which provides stability and resources for future growth and innovation.
The company has a moderate price-to-earnings (P/E) ratio of 21.94, which is reasonable for a company in the pharmaceutical sector, indicating that the stock may be fairly valued compared to its earnings.

Sanofi
Bear Case

Investors should be bearish about investing in Sanofi for these reasons:

Despite recent positive ratings, the stock has experienced fluctuations, including a recent drop to $50.76, which may indicate volatility and uncertainty in the market.
Analysts have issued mixed ratings, with some lowering their expectations, such as StockNews.com reducing their rating from "buy" to "hold," which could signal caution for potential investors.
Sanofi's beta of 0.58 suggests lower volatility compared to the market, but it also indicates that the stock may not perform as strongly during market upswings, potentially limiting growth opportunities.
Only 14.04% of the stock is owned by institutional investors, which may suggest a lack of widespread confidence among larger investment entities.
The company's P/E/G ratio of 1.01 indicates that the stock is fairly valued in relation to its growth rate, which may not provide enough upside for aggressive investors seeking high-growth opportunities.

SNY Forecast - Frequently Asked Questions

: According to the research reports of 5 Wall Street equities research analysts, the average twelve-month stock price forecast for Sanofi is $62.50, with a high forecast of $65.00 and a low forecast of $60.00.
: 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sanofi in the last twelve months. There are currently 2 hold ratings, 1 buy rating and 2 strong buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SNY shares.
: According to analysts, Sanofi's stock has a predicted upside of 21.05% based on their 12-month stock forecasts.
: Over the previous 90 days, Sanofi's stock had 2 upgrades by analysts.
: Sanofi has been rated by research analysts at Deutsche Bank Aktiengesellschaft, Sanford C. Bernstein, and The Goldman Sachs Group in the past 90 days.
: Analysts like Sanofi more than other "medical" companies. The consensus rating for Sanofi is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how SNY compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NASDAQ:SNY) was last updated on 4/15/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sanofi (SNY) Stock Forecast & Price Target